Novo Nordisk, Novartis, Gilead Sciences, AbbVie and AstraZeneca,
-Novo Nordisk announced that new data presented at the Annual Meeting of the European Association for the Study of Diabetes (EASD) show that the majority of type 2 diabetes patients receiving the recently launched Tresiba® plus metformin were able to maintain good glycemic control. New Study Demonstrates Efficacy Throughout 2.5 Years for Tresiba details the 26-week study.
-World Pharma News reports that Novartis continues its commitment to fight malaria. Malaria No More and Novartis Launch Power of One, a Global Digital Fundraising Campaign to Help Eliminate Malaria Deaths reveals how Novartis will support the campaign financially and donate up to three million treatments to match anti-malaria treatments funded by the public.
-Gilead Sciences announced in a press release the European Commission has granted marketing authorization for once-daily Tybost. European Commission Approves Gilead Sciences’ Tybost™, a New Boosting Agent for HIV Therapy gives detailed information about Tybost and how it’s an important factor in supporting treatment adherence.
-AbbVie found another opportunity to expand its pipeline in an effort to find a way to diversify its marketing effort. The FierceBiotech article, AbbVie Continues Deal Spree with $405M CF Tie-up with Galapagos, explains the new partnership that includes research in cystic fibrosis.
-Reuters has stated that US regulators have accepted an experimental fish oil-based heart drug from AstraZeneca. AstraZeneca Looks for New Heart Drug Approval by Next May reveals how cardiovascular medicine is a key area for AstraZeneca.
